UMB Bank N A MO reduced its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 1.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,986 shares of the biopharmaceutical company’s stock after selling 2,319 shares during the period. UMB Bank N A MO’s holdings in Gilead Sciences were worth $15,515,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Prospera Financial Services Inc increased its stake in shares of Gilead Sciences by 23.5% in the second quarter. Prospera Financial Services Inc now owns 11,235 shares of the biopharmaceutical company’s stock valued at $937,000 after buying an additional 2,138 shares during the last quarter. WealthTrust Axiom LLC increased its stake in shares of Gilead Sciences by 3.9% in the second quarter. WealthTrust Axiom LLC now owns 8,612 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 320 shares during the last quarter. Narwhal Capital Management increased its stake in shares of Gilead Sciences by 11.9% in the second quarter. Narwhal Capital Management now owns 26,820 shares of the biopharmaceutical company’s stock valued at $2,237,000 after buying an additional 2,855 shares during the last quarter. PGGM Investments increased its stake in shares of Gilead Sciences by 19.8% in the second quarter. PGGM Investments now owns 1,301,945 shares of the biopharmaceutical company’s stock valued at $108,608,000 after buying an additional 215,288 shares during the last quarter. Finally, HL Financial Services LLC increased its stake in shares of Gilead Sciences by 13.9% in the second quarter. HL Financial Services LLC now owns 76,018 shares of the biopharmaceutical company’s stock valued at $6,341,000 after buying an additional 9,292 shares during the last quarter. 77.94% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.27% on Friday, reaching $75.24. 11,149,150 shares of the company traded hands. The stock’s 50 day moving average price is $78.95 and its 200-day moving average price is $85.05. Gilead Sciences Inc. has a one year low of $74.92 and a one year high of $111.11. The stock has a market capitalization of $99.29 billion, a P/E ratio of 6.60 and a beta of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same period in the previous year, the business posted $3.15 earnings per share. Gilead Sciences’s revenue for the quarter was down 5.7% on a year-over-year basis. Equities analysts forecast that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.

Several brokerages recently commented on GILD. Piper Jaffray Cos. reduced their target price on shares of Gilead Sciences from $114.00 to $108.00 and set an “overweight” rating for the company in a report on Tuesday, July 26th. Royal Bank Of Canada cut their price objective on shares of Gilead Sciences from $120.00 to $105.00 and set an “outperform” rating for the company in a report on Tuesday, July 26th. Robert W. Baird reissued an “outperform” rating and issued a $122.00 price objective (down previously from $135.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Jefferies Group reissued a “hold” rating and issued a $93.00 price objective (down previously from $97.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Ten equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $104.71.

In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the transaction, the insider now directly owns 3,231,096 shares of the company’s stock, valued at $250,829,982.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $79.81, for a total transaction of $159,620.00. Following the transaction, the executive vice president now directly owns 64,122 shares in the company, valued at $5,117,576.82. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.